I.B.F. Management Ltd.
- SEC CIK
- 0001994849
No open-market purchases or sales filed in the past year.
Current role at each company
- ADXS Ayala Pharmaceuticals, Inc.Director, 10% Owneras of Mar 6, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists I.B.F. Management Ltd. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2023 (view filing)9:04 AM ET | Nov 17 | 4 days | Israel Biotech Fund I, L.P. and 4 others10% Owner | PPurchase | +43.8M | – | – | –27.6M after | Derivative10 lots |
| Oct 31, 2023 (view filing)7:08 AM ET | Oct 18 | 13 daysLate | Israel Biotech Fund I, L.P. and 4 others10% Owner | PPurchaseCommon Stock, par value $0.001 per share | +1.32M | $0.00 | $0 | New position1.09M after | 2 lots |
| Sep 29, 2023 (view filing)6:13 AM ET | Sep 1 | 28 days | Israel Biotech Fund I, L.P. and 4 others10% Owner | PPurchase | +1.74M | – | – | –434.8K after | AmendedDerivative2 lotsPrice outlierDuplicate filing |